PURCHASE AND SALE AGREEMENT by and between HEMISPHERX BIOPHARMA, INC., a Delaware corporation as Seller and CAPITAL REALTY & INVESTMENT CO., LLC, a New Jersey limited liability company as Purchaser For the sale and purchase of the following Property:...Purchase and Sale Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New Jersey
THIS PURCHASE AND SALE AGREEMENT (“Agreement”) is made this 8 day of January, 2018, by and between HEMISPHERX BIOPHARMA, INC., a Delaware corporation (the “Seller”), and CAPITAL REALTY & INVESTMENT CO., LLC, a New Jersey limited liability company (the “Purchaser”).
AMENDMENT NO. 2 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharna, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 28 of June 2017 (the “Amendment No. 2 Effective Date”).
AMENDMENT NO. 1 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This First Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of December 13, 2106 (the “Amendment No. 1 Effective Date”).
AMENDMENT NO. 3 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This third Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 14 February 2018 (the “Amendment No. 3 Effective Date”).
AMENDMENT NO. 4 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This fourth Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 26 March 2018 (the “Amendment No. 4 Effective Date”).
COMMON STOCK PURCHASE WARRANT hemispherx biopharma, inc.Common Stock Purchase Warrant • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received,_____________ or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance (the “Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Hemispherx BioPharma, Inc., a Delaware corporation (the “Company”), up to _____________shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
